T cell dynamics in chronic lymphocytic leukemia under different treatment modalities

Anna Vardi1,2,3, Elisavet Vlachonikola1,4, Despoina Papazoglou5, Fotis Psomopoulos1,3, Kostantia Kotta1, Nikolaos Ioannou5, Chrysi Galigalidou1,6, Katerina Gemenetzi1,6, Kostantinos Pasentsis1, Maria Kotouza1, Evdoxia Koravou2, Lydia Scarfó7, Michail Iskas2, Niki Stavroyianni2, Paolo Ghia7, Achilles Anagnostopoulos2, Anastasia Kouvatsi4, Alan G Ramsay5, Kostas Stamatopoulos1,3, Anastasia Chatzidimitriou1,3

1Institute of Applied Biosciences, CERTH, Thessaloniki, Greece; 2Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; 4Faculty of Sciences, Department of Genetics, Development and Molecular Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece; 5Lymphoma Immunology Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom; 6Democritus University of Thrace, Department of Molecular Biology and Genetics, Alexandroupolis, Greece; 7Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

SHORT TITLE: CLL T cell immunoprofiling over treatment

CONFLICT-OF-INTEREST DISCLOSURE

KS and AC received research funding from Janssen.
CORRESPONDING AUTHOR:

Anastasia Chatzidimitriou, PhD
Institute of Applied Biosciences, CERTH
57001 Thessaloniki, GREECE
Phone: +30.2310.498271
Fax: +30.2310.498270
e-mail: achatzidimitriou@certh.gr

Text word count: 4601
Abstract word count: 244
Number of figures: 6
Number of references: 45
Number of supplemental files: 1
TRANSLATIONAL RELEVANCE

Chronic lymphocytic leukemia (CLL) T cells display largely defective anti-tumor responses. From a clinical perspective, there is a clear need to optimize CLL immunotherapy, especially regarding minimal residual disease eradication. Boosting anti-tumor T cell responses could ideally fit this gap, and identifying the best combination treatment partners is of translational relevance.

We investigated the effect of treatment on CLL T cells in relation to: (i) treatment type (FCR versus ibrutinib versus rituximab-idelalisib), and (ii) clinical response.

In contrast to chemoimmunotherapy, B-cell receptor signaling inhibitors (BcRi) preserved pre-treatment T cell clones, which expanded further as treatment continued and the clinical response deepened. We found major clonotypes shared among different patients, raising the possibility of selection by conserved, CLL-associated epitopes. A concurrent restoration of T cell functionality with BcRi therapy arguably contributed to clinical response. Overall, this data provides rationale for designing combination strategies aiming to boost cytotoxic anti-tumor responses.
ABSTRACT

**Background:** Using next-generation sequencing (NGS), we recently documented T cell oligoclonality in treatment-naive chronic lymphocytic leukemia (CLL), with evidence indicating T cell selection by restricted antigens.

**Experimental Design:** Here, we sought to comprehensively assess T cell repertoire changes during treatment in relation to: (i) treatment type [fludarabine-cyclophosphamide-rituximab (FCR) versus ibrutinib (IB) versus rituximab-idelalisib (R-ID)], and (ii) clinical response, by combining NGS immunoprofiling, flow cytometry and functional bioassays.

**Results:** T cell clonality significantly increased at: (i) 3 months in the FCR and R-ID treatment groups, and (ii) over deepening clinical response in the R-ID group, with a similar trend detected in the IB group. Notably, in contrast to FCR that induced T cell repertoire reconstitution, B cell receptor signaling inhibitors (BcRi) preserved pre-treatment clones. Extensive comparisons both within CLL as well as against T cell receptor sequence databases showed little similarity with other entities, but instead revealed major clonotypes shared exclusively by CLL patients, alluding to selection by conserved CLL-associated antigens. We then evaluated the functional effect of treatments on T cells and found that: (i) R-ID upregulated the expression of activation markers in effector memory T cells, and (ii) both BcRi improved anti-tumor T cell immune synapse formation, in marked contrast to FCR.

**Conclusions:** Taken together, our NGS immunoprofiling data suggest that BcRi retain T cell clones that may have developed against CLL-associated antigens. Phenotypic
and immune synapse bioassays support a concurrent restoration of functionality, mostly evident for R-ID, arguably contributing to clinical response.
INTRODUCTION

The tumor microenvironment (TME) plays a pivotal role in the natural course of chronic lymphocytic leukemia (CLL). This is evidenced by ample immunogenetic cues suggesting selection of the malignant B cell clone by a restricted set of antigens, as well as by the remarkable clinical efficacy of drugs interfering with B-cell receptor signaling (BcR signaling inhibitors, BcRi).\textsuperscript{1-6} Although BcRi were developed to target the clonal B cells, accumulating data suggest a pleiotropic effect in the CLL microenvironment, particularly T cells, which may contribute to their clinical efficacy.\textsuperscript{7-15}

T cells are intimately implicated in CLL pathophysiology. Xenograft studies have highlighted the importance of trophic signals provided by T cells for the survival of the malignant clone.\textsuperscript{16} On the other hand, immunosurveillance by T cells is compromised in CLL, due to, amongst others, defective cytoskeletal signaling and lytic immune synapse formation following tumor immunosuppressive signaling.\textsuperscript{17-20} Therefore, delineating the mechanisms driving T cell tolerance rather than effective anti-tumor cytotoxic immune responses is highly relevant and could facilitate optimization of immunotherapy for CLL, with the aim of eradicating minimal residual disease.\textsuperscript{21, 22}

Studies employing different methodologies have demonstrated the existence of T cell expansions in CLL.\textsuperscript{23-27} Recently, we investigated the role of antigenic stimulation in shaping the T cell repertoire in treatment-naive CLL using next-generation sequencing (NGS).\textsuperscript{28} Our study confirmed T cell oligoclonality, with major (high-frequency) clonotypes persisting and further expanding overtime as well as
clonotypes shared among different patients, which appeared to be CLL-specific. Overall, these findings pointed towards selection of T cells by CLL-associated antigenic epitopes.

On these grounds, we sought to comprehensively assess the effect of treatment on CLL T cell repertoire dynamics by combining NGS immunogenetics, flow cytometry and immune synapse bioassays, in order to investigate associations of quantitative and/or qualitative changes with the type of treatment and clinical response. Considering recent data about collateral effects of BcRi treatment on T cells, \(^{7-14, 29}\) we focused on patients receiving ibrutinib (IB) or rituximab-idelalisib (R-ID) which we compared to patients receiving standard chemoimmunotherapy with the fludarabine-cyclophosphamide-rituximab (FCR) regimen.

In sharp contrast to chemoimmunotherapy, BcRi were found to preserve pre-treatment T cell clones. These clones expanded further as treatment continued and clinical response deepened, particularly in the case of R-ID. Repertoire comparisons revealed major clonotypes shared by different CLL patients but very few “public” clonotypes (i.e. also present in other conditions), suggesting selection by conserved CLL-associated epitopes. Moreover, phenotypic and immune synapse bioassays supported a concurrent restoration of T cell functionality with BcRi therapy, mostly evident for R-ID, arguably contributing to clinical response. Taken together, this data provides a rationale for designing combination strategies aiming to boost cytotoxic anti-tumor responses.
METHODS

Patient group

We analyzed samples from 28 CLL patients treated in two centres (Thessaloniki, Greece; Milan, Italy) with FCR (n=9), IB (n=15), and/or R-ID (n=10). Patients were selected on the basis of sample availability. Demographic and clinicobiological characteristics are provided in Suppl. Table 1. For 22 patients, samples were collected over the 1st line of treatment, either FCR or BcRi. For the remaining 6/28 patients, we analyzed samples collected over consecutive lines of treatment (1st line FCR/2nd line IB, n=3; 1st line FCR/2nd line R-ID, n=2; 1st line IB/2nd line R-ID, n=1). In all cases, samples post-treatment initiation were analyzed in relation to a respective pre-treatment initiation sample. In total, we analyzed 98 peripheral blood (PB) samples: (i) for patients who received FCR, we analyzed samples collected pre-treatment (n=9) and at 3 months after the completion of the 6 cycles (n=9, all in complete remission); (ii) for patients who received BcRi, we analyzed samples pre-treatment (n=25), at 3 months (n=25), 9 months (n=17), best clinical response (median 20 months, n=13)] while still on continuous BcRi treatment. Best response timepoint was defined by the attending physician, and corresponded to the maximal duration of BcRi treatment at the time the study was conducted (median time on BcRi treatment: 20 months), with the single exception of a patient who progressed on IB and proceeded to R-ID as 2nd line treatment. This patient was assessed only at the 3-month timepoint while on IB, at which he had achieved PR. Also, we included 6 bone marrow (BM) samples, collected along with the respective PB pre-treatment sample. A schematic representation of study cohort is provided in Figure 1A.
No patient had evidence of infection at sampling. All patients were negative for HBV DNA, anti-HCV and anti-HIV I/II. We carefully excluded patients who developed rituximab-related late-onset neutropenia (R-LON), as it is known to be mediated by cytotoxic T cell clones.\textsuperscript{30} The local Ethics Review Committee approved the study and written informed consent form was obtained from all individuals in accordance with the Declaration of Helsinki.

\textit{Next-generation sequencing, definitions and interpretation}

TRBV-TRBD-TRBJ gene rearrangements were RT-PCR amplified and subjected to paired-end NGS (MiSeq, Illumina), as previously described.\textsuperscript{28} For all samples, the starting absolute T cell count exceeded 0.5x10\textsuperscript{6} cells to ensure adequate repertoire profiling depth. Paired-end protocol allowed sequencing of the TRB complementarity-determining region 3 (CDR3) twice/read, thus increasing the accuracy of results. In order to further increase the accuracy of results, raw reads were processed through a purpose-built bioinformatics pipeline performing: (i) length/quality filtering of raw reads; (ii) merging of filtered-in paired reads via local alignment; (iii) length/quality filtering of stitched sequences.\textsuperscript{28} Detailed length, quality and overlap rules are provided in Suppl. Table 2. Importantly, no base calls of Q-score<30 were allowed in the 75 nucleotide stretch preceding the FGXG motif at the start of TRB FR4, thus further increasing the CDR3 sequencing reliability. Filtered-in sequences were submitted to IMGT/HighV-QUEST (http://www.imgt.org), and metadata was processed by a validated bioinformatics algorithm designed for clonotype computation and repertoire analysis (Figure 1B).\textsuperscript{28, 31} Only productive, in-frame
TRBV-TRBD-TRBJ gene rearrangements with functional TRBV genes were included in the analysis. TRBV-TRBD-TRBJ gene rearrangements carrying TRBV genes with <95% germline identity were also discarded as sequences with unacceptable error rate, given the lack of somatic hypermutation in T cells.

Clonotypes were computed as unique pairs of TRBV genes and CDR3 amino acid sequences within a sample. Clonotypes were considered expanded when they contained ≥2 sequences, otherwise they were considered as "singletons". The 10 most expanded clonotypes within a sample are referred to as "major". The relative frequency of each clonotype/sample was calculated as the number of rearrangements corresponding to the clonotype divided by the total number of productive, filtered-in rearrangements for that particular sample.

For TRB gene repertoire analysis, clonotypes rather than single rearrangements were considered in order to avoid potential biases due to expansion following antigenic stimulation, i.e. individual TRBV gene frequencies within a sample were calculated as the number of clonotypes using particular TRBV genes over the total number of clonotypes. Each category of samples (PBMCs, BM) was analyzed separately.

**Inter-patient and across entities clonotype comparison**

We determined the major clonotypes of all CLL samples included in the study (n=563 unique clonotypes, i.e. 10 major clonotypes of each sample removing duplicate values such as clonotypes which persisted in overtime analysis of the same patient or clonotypes shared among different patients) and compared them across CLL patients of this cohort, and against: (i) all T cell clonotypes from our previous NGS study involving treatment-naive CLL patients (n=1,105,728),28 (ii) T cell clonotypes
from 15 healthy donors (NGS study by our group, n=573,651), (iii) HHV-4 (Ebstein-Barr virus, EBV), HHV-5 (cytomegalovirus, CMV), and BK virus-specific T cell clonotypes (anti-viral T cell NGS study by our group, n=169,502), (iv) non-redundant, well-annotated, unique T cell clonotypes retrieved from public databases (n=17,024), and (v) T cell clonotypes from previous low-throughput immunoprofiling studies (classic subcloning followed by Sanger sequencing) in clinical monoclonal B cell lymphocytosis (high-count MBL, n=545), as well as clinical entities associated with clonal T cell expansions [R-LON (n=283), chronic idiopathic neutropenia (CIN, n=576), large granular T cell leukemia (T-LGL, n=932)].

**Flow cytometry**

Multi-color flow cytometry (FACSCanto II cell analyzer, BD Biosciences) was performed to investigate the expression of activation and exhaustion markers (CD25, CD38, CD69, HLA-DR and PD1, respectively) in functionally distinct T cell subpopulations, namely: (i) CD4⁺ and CD8⁺ naive T cells (CD45RA⁺/CCR7⁺), (ii) CD4⁺ and CD8⁺ central memory T cells (CM, CD45RO⁺/CCR7⁺), (iii) CD4⁺ and CD8⁺ effector memory T cells (EM, CD45RO⁺/CCR7⁺), and (iv) CD4⁺ and CD8⁺ terminal effector memory RA cells (TEMRA, CD45RA⁺/CCR7⁺). Eight patients (R-ID, n=4; IB, n=4) pre-treatment and at the 3-month timepoint were analyzed, as shown in Figure 1A.

Viably frozen peripheral blood mononuclear cells were thawed and resuspended in PBS (15 × 10⁶ cells in 1 mL) and incubated with pretitrated Abs to cell-surface markers at 4°C for 20 minutes. CD45 V500, CD3 V450, CD4 PerCP, CD4 PE-Cy7, CD8 PE-Cy7, CCR7 APC-Cy7, CD45RO FITC, CD45RA FITC, CD69 PE, CD25 APC, CD38 PerCP, HLA-DR PE and PD1 APC were used (BD Biosciences). Live lymphocytes were gated...
by forward and side scatter, CD45 positive plus 7AAD negative staining. Data were analyzed using the Kaluza flow cytometry analysis software (Beckman Coulter) (Suppl. Fig. 1).

An acquisition cut-off of 20,000 CD3\(^+\) live cells/sample was applied to ensure reliable representation of all studied T cell subpopulations, as well as uniformity across samples. For T cell activation/exhaustion analysis, results were expressed as the proportion of cells expressing antigens of interest (percent positive staining).

**Immune synapse bioassays, confocal microscopy and quantitative image analysis**

Tumor cell-T cell conjugate assays were designed to test the ability of CLL T cells to form immune synapses with autologous tumor cells. Negatively selected viable CD3\(^+\) T cells (1x10\(^6\)) from untreated, FCR- or BCRi-treated patients were conjugated with equal numbers of autologous CLL tumor cells acting as antigen presenting cells pulsed with super-antigen cocktail and stained with CMAC blue dye (ThermoFisher Scientific) according to the manufacturer’s instructions. Cell conjugates were incubated for 15min at 37°C, 5% CO\(_2\). Immunofluorescent labeling was done using Cytofuge2 cell concentrator, as described previously.\(^{19}\) Antibodies (Abs) for rhodamine phalloidin (F-actin staining) and perforin (Alexafluor 488 conjugated) were applied for 45 minutes at 4°C in 5% goat serum (Sigma-Aldrich) solution. After washing, cell specimens were sealed with 22×32 mm coverslips using fluorescent mounting (Dako). Images were captured with an A1R confocal microscope (Nikon) using a 63× oil objective with NIS- Elements software Version 5.01 imaging software (Nikon) and fluorescence was acquired sequentially. The specificity of staining was optimized using isotype-control Abs. Blinded confocal images (n=3 per treatment
group) were analyzed using NIS-Elements software Version 5.01 to measure the F-actin (red fluorescent channel) and perforin (green fluorescent channel) polarization at contact sites and immune synapses using relative recruitment index (RRI) analysis. RRI is calculated as the ratio of F-actin/perforin mean fluorescent intensity at the immune synapse area to the respective value at a cellular membrane area not involved in an immune synapse (RRI<1 indicates a non-polarized, dysfunctional immune synapse). RRI values were expressed as mean value +/- SEM.

**Statistical analysis and visualization tools**

Descriptive statistics for discrete parameters included counts and frequency distributions. The significance of bivariate/multivariate relationships between variables was assessed using the Student t-test, as well as the non-parametric Wilcoxon (for paired values) and Mann-Whitney tests. For all comparisons a significance level of p=0.05 was set.

By applying the Wilcoxon-signed rank test for matched pairs, the power of the NGS analysis ranges from 92% (for the most populated comparison, i.e. pre-IB versus IB at 3 months, n=15 samples) to 53% for the least populated comparisons, i.e. pre-R-ID, R-ID at 3 months, R-ID at 9 months versus R-ID at best response, n=5 samples). A table with power values for each paired comparison is provided in Supplemental Material (Suppl. Table 3).

All statistical analyses were performed using the statistical Package GraphPad Prism version 5.03 (GraphPad Software, Inc., San Diego, USA). For data visualization, either publicly available software (http://circos.ca, https://CRAN.R-project.org) or purpose-built R-tools were utilized.
Data Sharing Statement

Raw sequence data have been submitted to the Sequence Read Archive (SRA);

BioProject ID: PRJNA552792
RESULTS

The T cell repertoire in CLL is skewed both pre- and post-treatment initiation in all treatment subgroups, with clonal expansions

First, we profiled by NGS the TR gene repertoire in terms of clonality and TRB gene usage. Overall, 23,262,732 TRBV-TRBD-TRBJ sequences were obtained, of which 20,347,768 (87.5%, median 155,479/sample) passed filters and were further analyzed. The median number of distinct clonotypes/sample was 11,420 (range: 2672-54,045); the median number of expanded clonotypes and singletons/sample was 5287 (range: 772-26,501) and 6417 (range: 1500-32,428), respectively.

All CLL patient blood samples showed a T cell oligoclonal profile. The median T cell clonality of all analyzed samples, calculated as the cumulative frequency of the 10 major clonotypes/sample, was 37.5% (range 8.1-70.5%).

Nine TRBV genes accounted for almost half of the total repertoire both pre-treatment and at the 3-month timepoint (46.8% and 47.6% of the total repertoire, respectively). The relative frequency of each gene did not particularly differentiate over treatment, nor amongst treatment groups (FCR, IB, R-ID) (Suppl. Figure 2A). The single exception concerned the TRBV28 gene, which was underrepresented in the R-ID group both pre-treatment and at the 3-month timepoint [3.0%/3.4% versus 5.1%/5.1% in the FCR group (p<0.01) versus 4.5%/4.6% in the IB group (p<0.01), respectively]. For both the IB and the R-ID groups, where the repertoire was studied beyond the 3-month timepoint, the TRBV gene frequency remained relatively stable overtime and with deepening clinical response (Suppl. Figure 2B).
In conclusion, the T cell repertoire was skewed in all examined subgroups, with restricted TRB gene usage and significant clonal expansions.

**T cell clonality increases over treatment and may be associated to clinical response**

We then tested clonality dynamics over treatment and explored associations with clinical response. At cohort level (n=28 patients), circulating T cell clonality increased after treatment [median values from 30.3% pre-treatment to 38.8% (p<0.05), 41.9% (p<0.05) and 46.2% (p<0.01) at the 3-month, 9-month, and deepest clinical response timepoint, respectively].

Within different treatment groups, T cell clonality increased at the 3-month timepoint in the case of FCR (from 28.8% to 46.9%, p<0.05) and R-ID (from 33.0% to 39.1%, p<0.01), but not IB (from 33.3% to 31.2%, p: 0.99). For the IB and R-ID groups, longitudinal analysis over treatment showed a gradual increase of T cell clonality, related to the depth of clinical response, reaching statistical significance in the case of R-ID [from 33.0% pre-treatment to 39.1% at 3 months (p<0.01), 46.0% at 9 months (p<0.01) and 46.1% at best clinical response (p: 0.13)], but not IB [from 33.3% pre-treatment to 31.2% at 3 months (p: 0.99), 39.1% at 9 months (p: 0.44) and 42.1% at best clinical response (p: 0.17)] (Figure 2).

We also performed analyses where clonality definition was modified in order to include a larger proportion of the repertoire (calculated as the cumulative frequency of the 20 or 50 most expanded clonotypes/sample, instead of 10). These analyses, as well as plots of clonotype frequency in relation to its rank in the repertoire, showed that the gradual increase of clonality resulted from the expansion of the major clonotypes, further alluding to their clinicobiological relevance (Suppl. Figure 3).
Differential impact of chemoimmunotherapy versus BcRi on the T cell repertoire

To further study clonal dynamics over treatment, we evaluated clonal persistence overtime for each treatment group. We found that chemoimmunotherapy (FCR) resulted in T cell repertoire renewal through ablation and immune reconstitution, whereas BcRi retained most major pre-treatment T cell clones (median number of major pre-treatment clonotypes that persisted at the 3-month timepoint: 2/10 for FCR versus 8/10 for IB versus 7/10 for R-ID) (Figure 3A). Overlap analysis of the total repertoire pre- and post-treatment per group showed similar results (Figure 3B). Furthermore, in the case of BcRi where the repertoire was studied longitudinally over treatment, repertoire preservation persisted over time (Figure 3C).

Clonotype comparisons document the existence of ‘disease-biased’ T cell clonotypes

To obtain insight into the antigenic specificities of the expanded T cell clones, we next listed all unique major clonotypes from our cohort (n=563 clonotypes) and compared them (i) across patients, and (ii) against T cell clonotypes from various entities, as detailed in the Methods section.

Thirty-two of the 563 clonotypes were shared among different CLL patients (Suppl. Table 4), while 18/563 were found in another entity and/or healthy donors ("public" clonotypes") (Figure 4). In particular, "public" clonotypes corresponded to 9 matches with T cell clonotypes of herpes virus specificity (CMV, EBV), 2 matches with clonotypes of herpes virus specificity (EBV) that were also found in patients with CIN, and 5 matches with T cell clonotypes from healthy donors. Importantly, of the 32 major clonotypes that were shared among CLL patients, only 9 were "public", ...
whereas the remaining 23 (23/563, 4.1% of all major clonotypes of our cohort) were shared exclusively by CLL patients, alluding to selection by CLL-associated antigens ("CLL-specific"). Of these 23 “CLL-specific” clonotypes, 3 were shared among 4 different patients, 5 among three different patients, and the remaining 15 among pairs of patients.

**Major CLL-specific T cell clonotypes expand further over treatment**

Considering the above, we repeated our clonality analysis excluding all "public" clonotypes, with similar results. More specifically, clonality significantly increased at the 3-month timepoint in the case of FCR (from 20.8% to 46.9%, p<0.01) and R-ID (from 32.9% to 38.8%, p<0.01), but not IB (from 33.3% to 31.2%, p=0.50). Overtime, clonality increased in both the R-ID and IB group, however reaching statistical significance only in the former [R-ID: from 32.9% to 38.8% at 3 months (p<0.01), 44.4% at 9 months (p<0.01) and 39.5% at best clinical response (p:ns); IB: from 33.3% to 31.2% at 3 months (p:ns), 39.1% at 9 months (p:ns) and 42.1% at best clinical response (p:ns)] (Figure 5).

**Pre-treatment major T cell clonotypes from the peripheral blood are also found in the bone marrow**

For 6 patients (R-ID, n=3 and IB, n=3), synchronous pre-treatment PB and infiltrated BM samples were available. We performed pairwise comparison of the T cell repertoires, to investigate for the presence of PB major clonotypes within the respective BM repertoire. Excluding "public" clonotypes, all PB major clonotypes of
these patients (n=56) were identified within the respective BM repertoires, and 37/56 (66.0%) were listed among the major clonotypes/BM sample.

**Idelalisib-based therapy increases the expression of activation markers on effector memory T cells**

NGS immunoprofiling showed that T cell clonality increased with BcRis, with major clones persisting and further expanding over time. In some cases, these clones were shared among different CLL patients but not found in other entities, suggesting that they may have developed in response to CLL-specific antigens. Therefore, we next wanted to investigate the impact of treatment on T cell functionality, so as to uncover a possible link between these T cell expansions and anti-tumor responses that could contribute to the deepening of clinical response.

To this end, we examined distinct T cell subsets of 8 patients (R-ID, n=4; IB, n=4) pre-treatment and at 3 months for the expression of activation and exhaustion markers by flow cytometry. While the relative frequencies of these T cell subsets, namely CD4\(^+\) and CD8\(^+\) naive, central memory (CM), effector memory (EM) and terminal effector memory (TEMRA) T cells, did not significantly fluctuate over treatment (data not shown), the expression of activation markers significantly increased post-treatment in the R-ID group compared to the IB group. More specifically, we noted increased expression of: (i) CD69 in CD4\(^+\) EM (median fold change 2.0 versus 0.5, p<0.01); (ii) CD25 in CD8\(^+\) TEMRA (median fold change 1.3 versus 0.5, p<0.01), and (iii) CD38 in CD8\(^+\) EM (median fold change 1.6 versus 0.3, p<0.05) and TEMRA T cells (median fold change 1.1 versus 0.3, p<0.05) (**Suppl. Figure 4**).
**BcRi treatment improves T cell immune synapse formation with tumor cells**

Given that T cell dysfunction in CLL has been linked to impaired immune synapse formation, we finally investigated the impact of therapy on immune function by characterizing the ability of patient T cells to form synapse interactions with autologous baseline CLL cells in 13 patients pre-treatment and at 3 months (FCR, n=3; R-ID, n=5; IB, n=5). Confocal microscopy with quantitative image analysis showed that T cells from FCR-treated patients did not improve their ability to form synapse interactions (Figure 6A) whereas both BcRi increased the formation of polarized F-actin immune synapses with tumor cells (R-ID, IB, p<0.05; FCR, p=0.99) (Figure 6B and C). We also detected enhanced polarization of the cytolytic molecule perforin towards tumor cells in IB-associated T cell synapses (p<0.05) (Figure 6B). For 2 patients (R-ID, n=1; IB, n=1), RRI immune synapse analysis was also performed at the deepest clinical response timepoint. These assays revealed no change in T cell synapse formation at the deepest response timepoint reached with IB therapy (25 months) compared to the 3 month timepoint, that may suggest a normalization of T cell function. In contrast, for the patient who received R-ID, deeper clinical response (12 months) correlated with a further increase in polarized immune synapse function (Figure 6D).
DISCUSSION

In the present work we sought to investigate the effect of different types of treatment on T cells from CLL patients. Given the pleiotropic impact of BcRi on the CLL microenvironment, we focused on BcRi as currently used for CLL treatment (IB and R-ID) and compared with standard chemoimmunotherapy (FCR). Our study cohort was significantly enriched for CLL cases with unmutated IGHV genes, the main reason being that these cases are most frequently in need of treatment, especially BcRis. While it cannot directly account for IGHV-mutated CLL, all reported findings concern pair-matched samples (samples of the same patient over time), therefore we argue that IGHV mutational status is not an influent.

We report that T cell clonality significantly increased after treatment with FCR and over treatment with R-ID, and, at least in the case of R-ID, this correlated with the depth of clinical response, peaking at 9 months. A similar trend was detected with IB therapy, however an increase in clonality occurred later in the course of treatment (≥9mo) and did not reach statistical significance, possibly due to the smaller number of samples at more advanced timepoints.

At first glance, the IB results may seem contradictory to a recent study by Yin et al, reporting that IB therapy resulted in TR repertoire diversification, however, certain experimental and analytical differences may explain this. From the start, the use of different clonotype definitions renders the results incomparable: Yin et al reported outcomes on the 1000 most frequent clonotypes (defined as productive unique sequences per sample), while in the present study we focused on the 10 most frequent clonotypes, defined on the basis of unique amino acid CDR3 sequence and
the same IGHV gene. Moreover, Yin et al \cite{Yin2017} utilized the ImmunoSEQ platform by Adaptive Biotechnologies, whereas we applied customized, purpose-built bioinformatics algorithms with intentionally strict length and quality filtering. Of note, the increasing T cell repertoire diversity reported by Yin mostly results from an increasing number of singletons. When we performed the same type of analysis in our cohort, following clonotype definition as per the Yin et al study, we also found an increase of the singleton fraction at the 9-month timepoint, although not reaching statistical significance. Besides, Yin et al \cite{Yin2017} mention that 6/16 dominant TRBV-TRBJ usages persist and further expand over 12 months of IB therapy, and therefore speculate antigenic stimulation, in an analogy to our results. Finally, Yin et al \cite{Yin2017} comment on repertoire diversity by focusing on the emergence of new low-frequency clones over treatment, while, we, on the other hand, focus on the dynamics of the most frequent clones on the consideration that these are the most biologically relevant, and dwell into the hypothesis that may have expanded in response to tumor antigens. We do not comment on repertoire diversity; this may be associated with infectious risks and complications, as hypothesized by Yin et al, but is most probably irrelevant to the dynamics of anti-tumor clones.

Somewhat expectedly, FCR increased T cell clonality through repertoire ablation and reconstitution, probably reflecting a lymphotoxic effect that is restored overtime. Indeed, in a patient who received FCR and was studied prospectively, the increase of clonality at 3 months post-treatment was restored to pre-treatment levels by 9 months. In sharp contrast, BcRi did not reconstitute the T cell repertoire, retaining pre-treatment major T cell clones during therapy, and this was shown consistently for the longest follow-up period reported so far (median 20 months).
In order to obtain evidence as to whether the herein identified T cell clones might have expanded in response to CLL-associated antigens or not, we performed extensive comparisons against not only CLL/MBL sequence datasets, but also datasets from common herpes virus infections (CMV/EBV), healthy individuals, and entities mediated by T cell clones and found a significant number of major T cell clonotypes shared exclusively among CLL patients. This is remarkable given: (i) the random HLA background of our cohort, and (ii) the size of the comparison dataset (761,968 distinct TRBV-TRBD-TRBJ sequences). Therefore, this finding supports the existence of (neo)epitopes that are conserved across CLL. Along the same line of reasoning, it is worth noting that, for 3 patients studied over sequential lines of treatment, we found major clonotypes prior to 1st line FCR which disappeared at CR following FCR treatment, but re-emerged as major clonotypes at 1st relapse and persisted through 2nd line treatment with BcRi (data not shown).

In order to investigate the functional impact of treatment on CLL T cells, we studied the expression of activation and exhaustion markers on T cells. We found that R-ID upregulates certain activation markers including IL-2 receptor (CD25) in effector memory T cells compared to IB. Although this increase was arithmetically small, one needs to consider the fact that the frequency of each major clone is relatively low; therefore, even though we purposely focused our analysis on well-defined functional T cell subpopulations, the immunophenotypic activation of anti-tumor T cell clones may be "diluted" within the respective subpopulation. It is also possible that CLL T cells undergo phenotypic changes within tissue TMEs as well as the PB.

Considering that T cell dysfunction in CLL manifests in a defective ability to form immune synapses with tumor B cells, we investigated the effect of treatment on
immune synapse formation capability.\textsuperscript{18, 19} We found that, in contrast to FCR, BcRi improved immune synapse function and the recognition of tumor B cells. Interestingly, for the R-ID case which was studied beyond 3 months, this synapse restoration correlated with the depth of clinical response, however definite conclusions cannot be drawn as this was a single case. Improvement in immune synapse formation could be attributed to treatment-induced reduction in tumor load (as the T cell defect has been shown to be tumor-induced)\textsuperscript{18, 19}; however, the fact that this did not occur following FCR, the only treatment that led to complete remissions, argues in favor of a BcRi-specific effect on T cell function. Admittedly, the number of cases analyzed for immune synapse formation was limited, due to the substantial number of T cells required for all assays performed in this study. Notably, our results are in keeping with a previous report studying the immunomodulatory impact of FCR and R-IB.\textsuperscript{43}

Overall, NGS immunogenetics showed that BcRi retain T cell clones which can expand in parallel to deepening clinical response and possibly contribute to it. This is further corroborated by phenotypic and functional bioassays that demonstrate concurrent T cell activation and improvement in synapse recognition of tumor cells. Taken together, this study provides a rationale for designing future combinatorial therapeutic strategies aiming to boost anti-tumor immune responses. In support of this, recent studies have described the ability of both ibrutinib and idelalisib to enhance chimeric antigen receptor T-cell efficacy in CLL.\textsuperscript{44, 45} Future identification of the relevant CLL-associated antigens may eventually pave the way for stratified treatments by means of engineered T cells or peptide vaccines, especially if these epitopes are conserved among CLL patients.
ACKNOWLEDGMENTS

Supported in part by ERANET Transcan-2, Project Acronym: Novel, and the Hellenic Precision Medicine Network in Oncology. AV is recipient of a research fellowship from the European Hematology Association (EHA Physician Scientist Research Grant). We thank Theodoros Moysiadis for providing statistical assistance and Tsagiopoulou Maria for providing assistance with fishplot visualizations.
REFERENCES


19. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion

27


29. Garcon F, Okkenhaug K. PI3Kdelta promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1. *Immunology and cell biology* 2016; 94(5): 486-495. doi: 10.1038/icb.2016.1


FIGURE LEGENDS

**Figure 1. A. Schematic representation of the study cohort.** The FCR treatment group included 9 patients sampled prior to treatment and 3 months after completion of 6 FCR cycles. The IB group included 15 patients [12 receiving IB as 1st line treatment and 3, coming from the FCR treatment group, who relapsed after FCR and received IB as 2nd line treatment (the latter in dark grey)]. The R-ID group included 10 patients [7 receiving R-ID as 1st line treatment, 2 coming from the FCR treatment group who relapsed after FCR and received R-ID as 2nd line treatment (in light grey without outline), and 1 coming from the IB treatment group who relapsed on IB and received R-ID as 2nd line treatment (in light gray with outline)]. Sampling timepoints for the IB and R-ID treatment groups were 3 months, 9 months and at best clinical response while on continuous BcRi treatment. For 6 patients (underlined by a dashed line, IB, n=3; R-ID, n=3), bone marrow samples were also obtained in addition to PB prior to BcRi treatment. All samples were analyzed by NGS. Immune synapse bioassays were performed for 14 patients (marked with a dot; FCR, n=3; IB, n=6; R-ID, n=5). Flow cytometry for activation/exhaustion markers was performed for 8 patients (marked with a light grey dot IB, n=4; R-ID, n=4). **B. Schematic representation of the NGS pipeline.** TRBV-TRBD-TRBJ gene rearrangements were RT-PCR amplified and subjected to paired-end NGS (MiSeq, Illumina), as previously described. Instead of arbitrarily excluding low-frequency clonotypes, which may lead to underestimation of repertoire diversity, both the read-stitching algorithm as well as IRProfiler apply strict quality rules in order to maximize the accuracy of results.

**Figure 2. T cell clonality significantly increases after treatment with FCR and over treatment with R-ID.** The % cumulative frequency of the major clonotypes is depicted overtime per treatment group in a box-whisker fashion.

**Figure 3. FCR results in T cell repertoire renewal, whereas BcRi treatment retains pre-treatment T cell clones.** Venn diagrams are used to depict the overlap between the T cell repertoire pre-treatment and at the 3-month timepoint per treatment group, concerning (A) only the major T cell clonotypes, and (B) the total T cell repertoire. Overlap was calculated as the percentage of clonotypes of the pre-treatment repertoire which persisted at 3 months. (C) The T cell repertoire conservation remains over time for the IB and R-ID group.
Jaccard index, defined as the size of the intersection divided by the size of the union of the two sample sets \( J(A,B) = |A \cap B| / (|A| + |B| - |A \cap B|) \), is plotted on the \((y)\) axis. Comparisons concern the repertoire of each patient (dot) pre/3 months, pre/9 months and pre/deepest response, per treatment group. The median overlap (vertical line) remains practically the same over time for the IB and R-ID group, and significantly higher than for FCR.

**Figure 4. "Public" and CLL-specific clonotypes.** Of the 563 major clonotypes of the CLL cohort, 41 (7%) were found in other entities ("public") or shared among different CLL patients ("CLL-specific")

**Figure 5. Clonality analysis overtime, excluding "public" clonotypes.** (A) Clonality significantly increases after treatment with FCR and over treatment with R-ID. The % cumulative frequency of the major clonotypes is depicted overtime per treatment group in a box-whisker fashion, after having excluded clonotypes that were also found in other entities/healthy individuals ("public" clonotypes). (B) Persisting clonotypes expand overtime, especially in the case of R-ID. Fishplots depicting how the frequency of each persisting major clonotype changes in relation to the pre-treatment timepoint, again having excluded "public" clonotypes. Three characteristic cases of patients receiving R-ID and IB are depicted in the left and right column, respectively. Each ribbon represents a CLL-specific major clonotype which persists in all three timepoints over treatment (sequentially: pre-treatment, at 3 months, 9 months, and deepest response) and the thickness of the ribbon at each timepoint corresponds to the clonotype's relative frequency. The remaining repertoire is shown in white for all cases.

**Figure 6. BcRi treatment restores F-actin immunological synapses between CLL tumor cells and autologous T cells.** Untreated CLL tumor cells (CMAC dyed, blue) were conjugated with autologous negatively selected CD3⁺ T cells from CLL patient samples obtained prior initiation of treatment (pre) and 3 months post treatment. All conjugates per treatment time-point were acquired using a confocal microscope. Quantitative image analysis (relative recruitment index [RRI]) was used for the calculation of F-actin (red) and perforin (green) polarization towards the tumor cell in T-cell/B-cell conjugates of (A) FCR \((n=3)\), (B) ibrutinib.
(IB) (n=6) and (C) R-idelalisib (R-ID) (n=5) treated samples. Bar charts show the mean RRI values of all T-cell/B-cell CLL conjugates per treatment ± SEM. The confocal images show representative T-cell/B-cell conjugates for all treatments. Original magnification of immunofluorescence images ×63. (D) F-actin RRI analysis over deepening response for two patients on BcRi. Each dot corresponds to the mean RRI values ± SEM for treatment time-point. Differences between pre- and post-treatment samples were assessed by Wilcoxon signed-rank test. *p < 0.05
Fig. 1

A. 

- n=28 CLL pts, median age: 65.9y
- 26/28 with unmutated IGHV

- Pre-treatment
- FCR
- 3MO

- Pre-treatment
- IB
- 3MO
- 9MO

- Pre-treatment
- R-ID
- 3MO
- 9MO

- Best response
- Median time on IB: 20 months
- n=8

- Best response
- Median time on R-ID: 19 months
- n=5

B. 

- NGS all samples (n=104: 98 PB / 6 BM samples)

- RT-PCR for TRBV-TRBD-TRBJ (BIOMED-2 protocol)

- Purified PCR products

- Indexed PCR enrichment

- Validate Library (qPCR & Bioanalyzer)

- Normalize and Pool Libraries

- NGS ≥300bp

- Stitching algorithm

  - a) Quality filters on raw reads (Q-score, sequence length, etc.)
  - b) Paired-end read stitching via local alignment
  - c) Quality filters on merged sequences (mean Q-score, % low-quality base calls)

- Annotation of filtered-in fasta sequences by IMGT/HighV-QUEST tool

- Meta-data analysis on IRProfiler (clonotype computation, repertoire extraction)
Fig. 2

% cumulative frequency of the 10 major clonotypes/sample

FCR pre
FCR 3MO
IB pre
IB 3MO
IB best response
R-ID pre
R-ID 3MO
R-ID best response

**

**
Fig. 3C

<table>
<thead>
<tr>
<th>FCR</th>
<th>IB</th>
<th>R-ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.10</td>
<td>0.10</td>
<td>0.10</td>
</tr>
<tr>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
</tbody>
</table>

0-3mo 0-3mo 0-9mo 0-deepest response 0-3mo 0-9mo 0-deepest response
Fig. 4

- Shared among 2 CLL pts
- Shared among 3 CLL pts
- Shared among 4 CLL pts
- Shared by two or more CLL pts + HSV
- Shared by two or more CLL pts + Healthy
- Healthy
- HSV
- R-LON
- HSV+CIN
- HSV+CIN+Healthy

- Shared exclusively among (2 or more) CLL pts
- Shared by 2 or more CLL pts + other entity
- Shared by 1 CLL pt + other entity
Fig. 5A
Clinical Cancer Research

T cell dynamics in chronic lymphocytic leukemia under different treatment modalities

Anna Vardi, Elisavet Vlachonikola, Despoina Papazoglou, et al.

Clin Cancer Res Published OnlineFirst July 2, 2020.

Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-19-3827

Supplementary Material
Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2020/07/02/1078-0432.CCR-19-3827.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2020/07/02/1078-0432.CCR-19-3827. Click on "Request Permissions“ which will take you to the Copyright Clearance Center's (CCC) Rightslink site.